Diagnostic Biomarkers and Metabolic Mechanisms of Polymyxin B-Induced Acute Kidney Injury

Background/Objectives: The clinical utility of polymyxin B (PB), a critical last–line antibiotic for multidrug–resistant Gram–negative infections, is severely compromised by acute kidney injury (AKI). However, the lack of specific diagnostic biomarkers and the incomplete understanding of pathogenic mechanisms pose substantial challenges to clinical management of PB–associated AKI.